Clinical Trial Results:
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)
Summary
|
|
EudraCT number |
2021-002461-18 |
Trial protocol |
DE BE HU ES NL GR AT PT IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1 |
This version publication date |
01 Sep 2022
|
First version publication date |
01 Sep 2022
|
Other versions |
v2 |
Summary report(s) |
Nektar_20-214-36_CSR synopsis_27Jul2022 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.